Vericel Corporation (VCEL) Stock Analysis
Momentum Cont setup
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $38.32, but acceptable to hold if already in. Reason: Concentration risk — Supplier: Matricel.
Vericel Corporation markets three FDA-approved therapies in the US: MACI (knee cartilage repair), Epicel (severe burn skin replacement), and NexoBrid (eschar removal for burn patients), targeting orthopedic surgeons and burn care specialists. Revenue comes from specialty... Read more
Hold if already holding. Not a fresh buy at $38.32, but acceptable to hold if already in. Reason: Concentration risk — Supplier: Matricel. Chart setup: Trend continuation, RSI 65, MACD bullish. Maintain position. Not compelling to add more. Score 6.3/10, moderate confidence.
Passes 8/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 45d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Recent developments
updated 2026-06-15Recent Developments — Vericel Corporation
Latest news
- NEWS VCEL (Vericel Corporation) reports 13.1 percent Q4 2025 EPS beat, shares fall 6.23 percent in today’s trading. - Earning — Newser positive
- NEWS Insider Sell: Paul Wotton Sells 10,000 Shares of Vericel Corp (V - GuruFocus — GuruFocus negative
- NEWS Vericel Corporation (VCEL) reports Q1 loss, beats revenue estimates - MSN — MSN positive
- NEWS Vericel Corporation (VCEL) reports Q1 loss, beats revenue estimates - msn.com — msn.com positive
- NEWS Vericel Corporation (VCEL) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance — Yahoo Finance positive
Generated 2026-06-15T18:11:47Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSupplierMatricel10-K Item 1: 'The Matricel Supply Agreement provides that Matricel will supply the ACI-Maix membranes exclusively to us during the term of the agreement'
- MEDIUMSupplierMediWound10-K Item 1A: 'The commercial success of NexoBrid in the U.S. is dependent, in part, on MediWound’s ability to timely manufacture and supply sufficient quantities of NexoBrid to meet customer demand'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $38.32, but acceptable to hold if already in. Reason: Concentration risk — Supplier: Matricel. Chart setup: Trend continuation, RSI 65, MACD bullish. Maintain position. Not compelling to add more. Target $48.22 (+25.8%), stop $35.65 (−7.5%), A.R:R 1.7:1. Score 6.3/10, moderate confidence.
Take-profit target: $48.22 (+25.8% upside). Target $48.22 (+25.8%), stop $35.65 (−7.5%), A.R:R 1.7:1. Stop-loss: $35.65.
Concentration risk — Supplier: Matricel.
Vericel Corporation trades at a P/E of 87.1 (forward 44.0). TrendMatrix value score: 5.6/10. Verdict: Hold.
14 analysts cover VCEL with a consensus score of 4.2/5. Average price target: $55.
What does Vericel Corporation do?Vericel Corporation markets three FDA-approved therapies in the US: MACI (knee cartilage repair), Epicel (severe burn...
Vericel Corporation markets three FDA-approved therapies in the US: MACI (knee cartilage repair), Epicel (severe burn skin replacement), and NexoBrid (eschar removal for burn patients), targeting orthopedic surgeons and burn care specialists. Revenue comes from specialty pharmacy sales (MACI) and hospital sales (Epicel/NexoBrid); net income was $16.5M in 2025. Matricel GmbH is the sole collagen membrane supplier for MACI manufacturing.